Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

• Ngā kaituhi matua: Si-Yang Liu (Author), Hao Sun (Author), Jia-Ying Zhou (Author), Guang-Ling Jie (Author), Zhi Xie (Author), Yang Shao (Author), Xian Zhang (Author), Jun-Yi Ye (Author), Chun-Xiang Chen (Author), Xu-Chao Zhang (Author), Qing Zhou (Author), Jin-Ji Yang (Author), Yi-Long Wu (Author)
• Hōputu: Pukapuka
• I whakaputaina: BMC, 2020-06-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Background The KRAS mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, the KRAS G12C-specific inhibitor AMG510 showed promising results in the phase I clinical trial. However, the frequenc...